Source: US Department of Health and Human Services
The Centers for Medicare & Medicaid Services’ (CMS’) final rule advances policies to promote the efficient operation of the Medicaid Drug Rebate Program (MDRP). This includes policies to implement new statutory authorities included in the Medicaid Services Investment and Accountability Act of 2019 (MSIAA) to address situations in which manufacturers incorrectly report or misclassify their drugs in the MDRP. The final rule also enhances MDRP integrity and strengthens policies that will ensure greater consistency and accuracy of drug information reporting, timely data collection, and efficient operation of the MDRP.
Identifying and Correcting Misclassified Drug Information and Addressing Late Reporting